Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health - Summary - MDSpire

Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health

  • By

  • Chi-Hsien Lee

  • Thi Phuong Nam Bui

  • Camille Petitfils

  • Ching Jian

  • Giselle C Wong

  • Anthony Puel

  • Tiphaine Le Roy

  • Samuel Bellais

  • Bouthaina Ben Abdallah

  • Mélanie Nehlich

  • Thomas Leicht

  • Manyi Jia

  • Lesley Hoyles

  • Massimo Federici

  • Jose Manuel Fernández-Real

  • Remy Burcelin

  • Marc-Emmanuel Dumas

  • Nathalie M Delzenne

  • Thomas Clavel

  • Sjef Boeren

  • Antonio Dario Troise

  • Andrea Scaloni

  • Giulio G Muccioli

  • Willem M De Vos

  • Matthias Van Hul

  • Patrice D Cani

  • July 1, 2026

  • 0 min

Share

Objective:

To investigate the fermentation pathway of myo-inositol to butyrate in Dysosmobacter welbionis and its implications for metabolic and liver health, highlighting its potential impact on human health.

Key Findings:
  • Dysosmobacter welbionis is prevalent in diverse human populations and shows heritability in monozygotic twins.
  • Relative abundance of D. welbionis is reduced in patients with metabolic-associated fatty liver disease (MASLD) and negatively correlates with fibrosis scores.
  • The study identifies a unique metabolic pathway in D. welbionis that converts myo-inositol into butyrate, emphasizing its ecological and therapeutic relevance.
Interpretation:

The findings suggest a potential protective role of D. welbionis in liver health and its relevance in metabolic disease management, indicating directions for future research.

Limitations:
  • The study primarily focuses on a specific gut bacterium and may not represent broader microbial interactions, such as those with other SCFA-producing bacteria.
  • Further research is needed to evaluate the clinical implications of D. welbionis in human health, particularly in diverse populations.
Conclusion:

D. welbionis may serve as a next-generation probiotic candidate for metabolic diseases, highlighting the importance of strain-level evaluation in probiotic development and its potential impact on therapeutic strategies.

Original Source(s)

Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health

  • by Chi-Hsien Lee, Thi Phuong Nam Bui, Camille Petitfils, Ching Jian, Giselle C Wong, Anthony Puel, Tiphaine Le Roy, Samuel Bellais, Bouthaina Ben Abdallah, Mélanie Nehlich, Thomas Leicht, Manyi Jia, Lesley Hoyles, Massimo Federici, Jose Manuel Fernández-Real, Remy Burcelin, Marc-Emmanuel Dumas, Nathalie M Delzenne, Thomas Clavel, Sjef Boeren, Antonio Dario Troise, Andrea Scaloni, Giulio G Muccioli, Willem M De Vos, Matthias Van Hul, Patrice D Cani

  • July 1, 2026

Related Content

Association of preoperative CT-derived visceral adipose tissue index with synchronous metastasis and metastasis-free survival after curative-intent surgery in colorectal cancer

Laparoscopic Transcystic Common Bile Duct Exploration for the Treatment of Choledocholithiasis Following Roux-en-Y Gastric Bypass

Gut microbiota and pediatric metabolic dysfunction–associated steatotic liver disease: clinical evidence and therapeutic implications